Literature DB >> 34422591

Comparison of the abilities of staging and risk stratification systems to predict the long-term structural recurrence in patients with differentiated thyroid carcinoma after total thyroidectomy and radioactive iodine remnant ablation.

Kyung Tae Nam1, Jae Hyun Park1, Gil Seong Moon1, Jong Ho Yoon1.   

Abstract

BACKGROUND: In patients with differentiated thyroid carcinoma (DTC), various staging and risk stratification systems have been applied to estimate long-term recurrence, which is a major issue during the postoperative follow-up period. However, the efficacy of these systems remains unclear in this context.
METHODS: The present historical cohort study included 510 patients with DTC who underwent a total thyroidectomy followed by radioactive iodine (RAI) remnant ablation. Enrolled patients were categorized according to the 8th edition of American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) Tumor Node Metastasis (TNM) staging system, the 2015 American Thyroid Association (ATA) initial risk stratification system, and the dynamic risk stratification (DRS) system. The ability of each system to predict long-term structural recurrence was compared using proportion of variance explained (PVE) by logistic regression models.
RESULTS: The median follow-up period was 108 months. Structural recurrence occurred in 7.6% of the patients (n=39/510). Disease-free survival (DFS) curves of the patients within each category in the TNM staging system, the ATA initial risk stratification system, and the DRS system were significantly different (P<0.001). The PVE of the DRS system (20.7%) was higher than those of the TNM staging system and the ATA initial risk estimates.
CONCLUSIONS: The DRS system may effectively predict long-term structural recurrence and guide long-term management and follow-up strategies in patients with DTC undergoing total thyroidectomy and RAI remnant ablation. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Differentiated thyroid cancer; disease-free survival (DFS); dynamic risk stratification (DRS); proportion of variance explained (PVE); structural recurrence

Year:  2021        PMID: 34422591      PMCID: PMC8340347          DOI: 10.21037/gs-21-8

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  22 in total

1.  Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer.

Authors:  Fabián Pitoia; Laura Ward; Nelson Wohllk; Celso Friguglietti; Eduardo Tomimori; Alicia Gauna; Rosalinda Camargo; Mario Vaisman; Rubén Harach; Fernando Munizaga; Sandro Corigliano; Eduardo Pretell; Hugo Niepomniszcze
Journal:  Arq Bras Endocrinol Metabol       Date:  2009-10

2.  Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients.

Authors:  Maria Grazia Castagna; Fabio Maino; Claudia Cipri; Valentina Belardini; Alexandra Theodoropoulou; Gabriele Cevenini; Furio Pacini
Journal:  Eur J Endocrinol       Date:  2011-07-12       Impact factor: 6.664

3.  Extent of surgery for intermediate-risk well-differentiated thyroid cancer.

Authors:  S Beenken; D Roye; H Weiss; M Sellers; M Urist; A Diethelm; H Goepfert
Journal:  Am J Surg       Date:  2000-01       Impact factor: 2.565

4.  Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy.

Authors:  Fernanda Vaisman; Denise Momesso; Daniel A Bulzico; Cencita H C N Pessoa; Fernando Dias; Rossana Corbo; Mário Vaisman; R Michael Tuttle
Journal:  Clin Endocrinol (Oxf)       Date:  2012-07       Impact factor: 3.478

5.  An expanded view of risk-group definition in differentiated thyroid carcinoma.

Authors:  B Cady; R Rossi
Journal:  Surgery       Date:  1988-12       Impact factor: 3.982

6.  In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response.

Authors:  Fernanda Vaisman; Hernan Tala; Ravinder Grewal; R Michael Tuttle
Journal:  Thyroid       Date:  2011-12       Impact factor: 6.568

7.  Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.

Authors:  Suyeon Park; Won Gu Kim; Eyun Song; Hye-Seon Oh; Mijin Kim; Hyemi Kwon; Min Ji Jeon; Tae Yong Kim; Young Kee Shong; Won Bae Kim
Journal:  Thyroid       Date:  2016-12-23       Impact factor: 6.568

8.  Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.

Authors:  I D Hay; E J Bergstralh; J R Goellner; J R Ebersold; C S Grant
Journal:  Surgery       Date:  1993-12       Impact factor: 3.982

9.  Intermediate-risk group for differentiated carcinoma of thyroid.

Authors:  A R Shaha; T R Loree; J P Shah
Journal:  Surgery       Date:  1994-12       Impact factor: 3.982

Review 10.  A Risk-adapted Approach to Follow-up in Differentiated Thyroid Cancer.

Authors:  Valentina D Tarasova; R Michael Tuttle
Journal:  Rambam Maimonides Med J       Date:  2016-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.